Abstract
Primary bone tumors are uncommon lesions and it would seem that interferon (IFN) therapy so far has been tried only in osteosarcoma. Osteosarcoma is a malignant disease of bone mainly afflicting young individuals with a predilection for the age group between 15 and 25 years. Its most common localization is the metaphyseal area of a long bone. In about 70% of all cases osteosarcoma is situated near the knee joint, i.e. in the distal femoral metaphysis, the proximal tibia, or the fibular metaphysis. The incidence of the disease may be estimated at approximately two cases per million inhabitants annually (Broström, 1979; Cancer Treatment Reports, 1978; Dahlin and Coventry, 1967). Like other primary malignant tumors of bone, osteosarcoma is therefore a rare type of tumor. Centralized management is consequently a prerequisite if a maximum of experience is to be gained in the diagnosis and treatment of these patients, and the Department of Orthopaedic Surgery at the Karolinska Hospital in Stockholm serves as a referral center for more than half of all bone tumor cases in Sweden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Balkwill, F., Taylor-Papadimitriou, J., Fantes, K., and Sebesteny, A. 1980, Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic (nude) mice. Europ. J. Cancer, 16:569.
Balkwill, F. 1979, Interferons as cell-regulatory molecules. Cancer Immuno1 Immunother., 7:7.
Broström, L.-A. 1979, On the natural history of osteosarcoma. Aspects on diagnosis, prognosis and endocrinology. Doctor’s thesis. Acta Orthop. Scand. Suppl., 183.
Broström, L.-Å., Aparisi, T., Ingimarsson, S., Lagergren, C., Nilsonne, U., Strander, H., and Söderberg, G. 1980, Can historical controls be used in current clinical trials in osteosarcoma? Analysis of prognostic factors in a historical and a contemporary group. Int. J. Rad. Oncol. Biol. Phys., 6:1711.
Broström, L.-Å. 1980, The combined effect of interferon and methotrexate on human osteosarcoma and lymphoma cell lines. Cancer Letters, 10:83.
Cancer Treatment Reports 1978, Proceedings of Osteosarcoma Study Group Meeting Febr. 1978. National Cancer Inst. (NIH), USA. Cancer Treat. Rep., 62:187.
Cancer Treatment Reports 1981, Proceedings of the International Symposium on Methotrexate. National Cancer Inst. (NIH) USA. Cancer Treat. Rep., 65 Suppl. 1:99.
Chirigos, M., and Pearson, J. 1973, Cure of murine leukaemia with drug and interferon treatment. J. Natl. Cancer Inst., 51:1367.
Crane, J., Glasgow, L., Kern, E., and Younger, J. 1978, Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J. Natl. Cancer Inst., 61:871.
Dahlin, D., and Coventry, M. 1967, Osteogenic sarcoma: A study of six hundred cases. J. Bone Jt. Surg., 45-A:101.
De Clercq, E., Georgiades, J., Edy, V., and Sobis, H. 1978, Effect of human and mouse interferon and of polyriboinosinic acid, poly-ribocytidylic acid on the growth of human fibrosarcoma and melanoma tumors in nude mice. Europ. J. Cancer, 14:1273.
Einhorn, S., and Strander, H. 1977, Is interferon tissue specific? Effect of human leukocyte and fibroblast interferons on the growth of lymphoblastoid and osteosarcoma cell lines. J. Gen. Virol., 35:573.
Glasgow, L., Crane, J., Jr., and Kern, E. 1978, Antitumor activity of interferon against murine osteogenic sarcoma cells in vitro. J. Natl. Cancer Inst., 60:659.
Glasgow, L., and Kern, E. 1981, Effect of interferon administration on pulmonary osteogenic sarcomas in an experimental murine model. J. Natl. Cancer Inst., 67:207.
Glasgow, L., Crane, J., Schleupner, Ch., Kern, E., Younger, J., and Feingold, D. 1979, Enhancement of resistance to murine osteogenic sarcoma in vivo by an extract of Brucella abortus (Bur-Pel). Infect, and Immun., 23:1.
Gresser, I. 1977, Antitumor effects of interferon in: “Cancer — A Comprehensive Treatise (Chemotherapy)” 5:525, Plenum Publ. Corp., New York.
Gresser, I., Maury, C., and Tovey, M. 1978, Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur. J. Cancer, 14:97.
Ingimarsson, S., Cantell, K., and Strander, H. 1979, Side effects of long-term treatment with human leukocyte interferon. J. Inf. Dis., 140:560.
Nilsonne, U., and Strander, H. 1981, Traitement de l’ostéosarcome par l’interféron et la chirurgie différenciée. Rev. Chir. Orthop., 67:193.
Paucker, K., Cantell, K., and Henle, W. 1962, Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology, 17:324.
Strander, H., and Einhorn, S. 1977, Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int. J. Cancer, 19:468.
Strander, H., Aparisi, T., Blomgren, H., Broström, L.-A., Cantell, K., Einhorn, S., Ingimarsson, S., Nilsonne, U., and Söderberg, G. 1982, Adjuvant interferon treatment of human osteosarcoma in: “Recent Results in Cancer Research 80”, Springer Verlag, Berlin.
Taylor, W., Ivins, J., Dahlin, D., Edmonson, J., and Pritchard, D. 1978, Trends and variability in survival from osteosarcoma, Mayo Clin. Proc., 53:695.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Plenum Press, New York
About this chapter
Cite this chapter
Broström, LÅ., Nilsonne, U. (1983). Bone Tumors. In: Sikora, K. (eds) Interferon and Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1170-6_14
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1170-6_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1172-0
Online ISBN: 978-1-4684-1170-6
eBook Packages: Springer Book Archive